Skeletal-related events (SREs) and survival among elderly patients with stage IV prostate cancer (PCa) in SEER Medicare data.

2014 ◽  
Vol 32 (31_suppl) ◽  
pp. 249-249
Author(s):  
Ebere Onukwugha ◽  
Young Kwok ◽  
Candice Yong ◽  
Christine Franey ◽  
C. Daniel Mullins ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
Bone Metastasis ◽  
Radiation Treatment ◽  
Stage Iv ◽  
External Beam Radiation ◽  
Beam Radiation ◽  
Palliative Radiation ◽  
All Cause Mortality ◽  
Skeletal Related Events

249 Background: Skeletal-related events occurring among PCa patients with bone metastasis include radiation to the bone (RttB), pathological fracture, spinal cord compression (SCC), and bone surgery (BS). There is no validated algorithm for identifying RttB using claims data. We investigated the prevalence and mortality impact of SREs across alternative claims-based algorithms for identifying RttB. Methods: We analyzed data for stage IV PCa cases identified between 2005 and 2009 in the Surveillance, Epidemiology, and End Results registry linked with Medicare claims. Fracture, SCC, and BS were identified from claims. Focusing on external beam radiation therapy, radiopharmaceutical therapy, intensity modulated radiotherapy and stereotactic radiosurgery, three approaches were created based on data visualization software: 1) radiation claim occurred after a claim with a bone metastasis (BM) code; 2) BM code directly coincided with the period of the radiation treatment episode; 3) either #2 or the duration of the radiation episode was less than or equal to 4 weeks. Regression models for all-cause mortality used these measures. Results: The study sample included 5,380 men with stage IV PCa. The median age of the sample was 77 years. All-cause mortality was 54% during median (mean) follow-up of 579 (656) days. The proportion who had any fracture, SCC, and BS was 23.2%, 6.3%, and 5.8%. Without taking BM code or duration of radiation into consideration, the proportion who received radiation therapy was 35%. Using approaches 1, 2 and 3 we have the following four results: 1) the proportion who received RttB was 22%, 18%, and 24%; 2) the prevalence of any SRE was 39%, 37%, and 41%; 3) among those with an SRE, the proportion receiving RttB was 57%, 50%, and 58%; 4) the adjusted hazard ratio (95% CI) associated with any SRE was 1.22 (1.13–1.33), 1.22 (1.12–1.33), and 1.25 (1.15–1.36). Conclusions: Among older men diagnosed with stage IV prostate cancer, approximately one in five men received palliative radiation and the mortality impact of skeletal-related events was comparable across alternative approaches to identifying palliative radiation.

Risk of second primary cancers after treatment for locoregional rectal cancer.

2013 ◽  
Vol 31 (15_suppl) ◽  
pp. 3578-3578 ◽  
Author(s):  
Chaitali Singh Nangia ◽  
Thomas H. Taylor ◽  
Walter Tsang ◽  
Jason Wong ◽  
Joseph Carmichael ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Rectal Cancer ◽  
Radiation Therapy ◽  
Small Intestine ◽  
Radiation Treatment ◽  
Uterine Cancer ◽  
External Beam Radiation ◽  
Second Primary ◽  
Beam Radiation ◽  
Pelvic Radiation

3578 Background: The risk of second primary colorectal cancers among rectal cancer patients has been described, but little is known about the risk of non-colorectal malignancies that may occur in the field of radiation. We attempted to quantify the risk, using data from the large population-based California Cancer Registry (CCR). Methods: We analyzed the CCR data for surgically-treated locoregional rectal cancer cases, diagnosed during the period 1988–2009. We excluded cases with second primary tumor (SPT) diagnosed within 12 months of initial diagnosis . Radiation treatment used was external beam radiation therapy. Standardized incidence ratios (SIR) with 95% confidence intervals (CI) were calculated to evaluate risk as compared to the underlying population after matching for age, sex, ethnicity, and time. Results: Of the study cohort of 13,418 rectal cancer cases, 1572 cases of SPTs were observed . The SIR was increased for small intestine cancer among cases receiving radiation treatment (4 cases observed vs. 1.01 cases expected; SIR=3.94, 95% CI 1.07-10.10) but not among cases lacking radiation treatment (4 observed vs. 4.45 expected; SIR=0.90, 5% CI 0.24-2.30). Among females treated with radiation, the SIR was increased for uterine cancer (12 observed vs. 5.59 expected; SIR=2.15, 95% CI 1.11 to 3.75) but not among cases lacking radiation therapy (23 observed vs. 26.17 expected; SIR=0.88, 95% CI 0.56-1.32). Among males receiving radiation treatment, the SIR for prostate cancer was decreased (23 observed vs. 69.78 expected; SIR=0.33; 95% CI 0.21 to 0.49) but of borderline significance among males lacking radiation therapy (243 observed vs. 276.97 expected; SIR=0.88, 95% CI 0.77-0.99). No significant differences were observed for cancers of the vagina, cervix, ovary, kidney, bladder, penis, testes, or leukemia based on prior radiation treatment for rectal cancer. Conclusions: Patients receiving pelvic radiation for treatment of rectal cancer have a subsequently higher than expected incidence of small intestine and uterine cancer. The incidence of prostate cancer appears to fall after pelvic radiation. These unexpected findings suggest complex relationships associated with radiation treatment for rectal cancer and SPT risk.

Bladder filling during radiation therapy for prostate cancer treatment: Assessment via bladder ultrasound scanner.

2018 ◽  
Vol 36 (6_suppl) ◽  
pp. 147-147
Author(s):  
Mark Raymond Waddle ◽  
Robin Landy ◽  
Karen Ryan ◽  
Katherine S. Tzou ◽  
William C Stross ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
Older Patients ◽  
Radiation Treatment ◽  
Bladder Volume ◽  
External Beam Radiation ◽  
Beam Radiation ◽  
Bladder Filling ◽  
Full Bladder ◽  
Ct Simulation

147 Background: Prostate cancer patients treated with external beam radiation therapy are instructed to present daily with a full bladder to decrease small bowel and bladder toxicity and to increase reproducibility of treatment. However, older patients may have difficulty presenting with full bladders and variation of bladder volume with treatment is unknown. The objective of this study was to assess bladder filling at the time of radiation treatment (RT) using a bladder ultrasound in patients undergoing treatment for prostate cancer. Methods: Patients with prostate cancer were prospectively enrolled prior to CT simulation from January to August 2017. Bladder volume was recorded during CT simulation and daily immediately prior to RT. Patients were instructed to drink 8-12 ounces of water 30-60 minutes prior to RT. Three bladder volume measurements were recorded daily and averaged at the time of each treatment. Average bladder volume during treatment and the number of treatments with low bladder volumes ( < 50cc, < 60cc, and < 100cc) were reported using descriptive statistics. Results: A total of 13 patients completed a median of 42 days of RT during the study period, resulting in 550 daily bladder volumes. Ten patients were treated definitively and 3 with salvage radiation after prostatectomy. The median age of patients in the study was 72 years. Older patients were statistically more likely to present with low bladder volumes, with percentage of treatments with a bladder volume less than 50cc, 60cc, and 100cc being 29%, 42%, and 66% compared to only 4%, 7%, and 18% in patients aged < 70 (P < 0.01). The average bladder volume at the time of CT simulation was 176cc ± 57cc and the average volume during treatment was 140cc± 93cc, which was not statistically different (P = 0.28). The bladder volume did not significantly change over the course of treatment. Conclusions: Older patients (age 70+) with prostate cancer were more likely to present for RT with low bladder volumes in this prospective study. Our findings suggest that older patients should receive extra counseling about bladder filling and/or may require less bladder filling at the time of CT simulation to provide more accurate bowel dosimetry measurements.

An algorithm to identify delivery of palliative radiation therapy using health care claims data: A proof of concept application of data visualization tools in the prostate cancer (PCa) setting.

2014 ◽  
Vol 32 (31_suppl) ◽  
pp. 248-248
Author(s):  
Ebere Onukwugha ◽  
James F. Gardner ◽  
Jinani Jayasekera ◽  
Sana Malik ◽  
Arif Hussain ◽  
...  
Keyword(s):  
Radiation Therapy ◽  
Bone Metastasis ◽  
Median Time ◽  
Data Visualization ◽  
Claims Data ◽  
Prostate Gland ◽  
External Beam Radiation ◽  
Diagnosis Code ◽  
Beam Radiation ◽  
Palliative Radiation

248 Background: Studies using healthcare claims data to investigate the burden of skeletal-related events employ various approaches to identify radiation to the bone (RttB) because billing codes available in claims data do not distinguish RttB from radiation to the prostate gland. We investigated the use of Eventflow data visualization software to identify components of a claims-based algorithm for RttB. Methods: We analyzed data for PCa cases identified in the Surveillance, Epidemiology, and End Results (SEER) registry data linked with Medicare claims. We identified two cohorts of individuals diagnosed between 2005 and 2009 and receiving radiation therapy, C1: diagnosed with incident bone metastasis (BM) according to SEER data; C2: diagnosed with incident stage IV M0 PCa. We defined radiation episodes of care from claims for external beam radiation therapy, radiopharmaceutical therapy, intensity modulated radiotherapy and stereotactic radiosurgery. Eventflow was used to compare cohorts and identify criteria for identifying RttB using claims data. Results: Application of inclusion criteria resulted in 1,491 individuals: 999 in C1 and 492 in C2. Median follow up was 596 days in C1 and 882 days in C2. Average age was 77 years in C1 and 73 years in C2. The median time to radiation therapy was 133 days in C1 compared to 171 days in C2. When requiring a BM diagnosis code on the radiation claim, the median time was 160 days in C1 compared to 514 days in C2. The median time to a fracture was 107 days in C1 compared to 369 days in C2. The median time to bone surgery was 183 days in C1 compared to 447 days in C2. The median time to spinal cord compression was 154 days in C1 compared to 375 days in C2. A BM diagnosis code concurrent with the radiation episode and radiation episodes less than or equal to 4 weeks in length were more common among C1 compared to C2. Conclusions: Analysis of data visualization output indicates that incorporating a bone metastasis code on claims concurrent with a radiation episode of care or the information regarding the length of the radiation episode will be useful for identifying receipt of palliative radiation using claims data.

Rates of Adverse IBD-Related Outcomes for Patients With IBD and Concomitant Prostate Cancer Treated With Radiation Therapy

2019 ◽  
Vol 26 (5) ◽  
pp. 728-733 ◽  
Author(s):  
Linda A Feagins ◽  
Jaehyun Kim ◽  
Anchalia Chandrakumaran ◽  
Cassandra Gandle ◽  
Katrina H Naik ◽  
...  
Keyword(s):  
Prostate Cancer ◽  
Inflammatory Bowel Disease ◽  
Radiation Therapy ◽  
Cancer Diagnosis ◽  
Bowel Disease ◽  
Radiation Treatment ◽  
Multiple Logistic Regression Analysis ◽  
External Beam Radiation ◽  
Beam Radiation ◽  
Inflammatory Bowel

Abstract Background Patients with inflammatory bowel disease (IBD) may be at higher risk for complications from radiation treatment for prostate cancer. However, available data are limited, and controversy remains regarding the best treatment approach for IBD patients who develop prostate cancer. Methods A retrospective cohort study across 4 Department of Veterans Affairs hospital systems. Patients with established IBD who were diagnosed and treated for prostate cancer between 1996–2015 were included. We assessed for flares of IBD, IBD-related hospitalizations, and IBD-related surgeries within 6, 12, and 24 months of cancer diagnosis and survival at 1, 2, and 5 years. Flares of IBD were those documented as such by the treating physician, and treatment changed accordingly. Results One hundred patients with IBD and prostate cancer were identified. Forty-seven were treated with either treatment with external beam radiation or brachytherapy, and 53 were treated with nonradiation modalities. Comparing cohorts with or without radiation treatment, there were no differences in baseline IBD characteristics, Charlson comorbidity index, or prostate cancer stage. Inflammatory bowel disease flares were 2-fold higher for radiation-treated patients within 6 months (10.6% vs 5.7%) and 6–12 months (4.3% vs 1.9%) after cancer diagnosis. On multiple logistic regression analysis, radiation treatment (adjusted odds ratio, 4.82; 95% confidence interval, 1.15–20.26) was a significant predictor of flares. However, rates of IBD-related hospitalizations or surgeries were not significantly different. Conclusions In this retrospective, multicenter study, 2-fold higher rates of flare were found within the first year after prostate cancer diagnosis for patients treated with radiation, but there were no differences in IBD-related hospitalizations or surgeries. Although patients should be counseled of these risks, avoidance of radiation therapy in IBD patients with prostate cancer is likely not necessary.

Evaluation of set-up errors and estimation of set-up margin during external beam radiation therapy of prostate cancer using electronic portal imaging device (EPID)

2021 ◽  
pp. 1-8
Author(s):  
Daryoush Khoramian ◽  
Soroush Sistani ◽  
Bagher Farhood
Keyword(s):  
Prostate Cancer ◽  
Radiation Therapy ◽  
Target Volume ◽  
External Beam Radiation ◽  
Beam Radiation ◽  
Cancer Radiotherapy ◽  
Imaging Device ◽  
Portal Images ◽  
Set Up ◽  
Prostate Cancer Radiotherapy

Abstract Aim: In radiation therapy, accurate dose distribution in target volume requires accurate treatment setup. The set-up errors are unwanted and inherent in the treatment process. By achieving these errors, a set-up margin (SM) of clinical target volume (CTV) to planning target volume (PTV) can be determined. In the current study, systematic and random set-up errors that occurred during prostate cancer radiotherapy were measured by an electronic portal imaging device (EPID). The obtained values were used to propose the optimum CTV-to-PTV margin in prostate cancer radiotherapy. Materials and methods: A total of 21 patients with prostate cancer treated with external beam radiation therapy (EBRT) participated in this study. A total of 280 portal images were acquired during 12 months. Gross, population systematic (Σ) and random (σ) errors were obtained based on the portal images in Anterior–Posterior (AP), Medio-Lateral (ML) and Superior–Inferior (SI) directions. The SM of CTV to PTV were then calculated and compared by using the formulas presented by the International Commission on Radiation Units and Measurements (ICRU) 62, Stroom and Heijmen and Van Herk et al. Results: The findings showed that the population systematic errors during prostate cancer radiotherapy in AP, ML and SI directions were 1·40, 1·95 and 1·94 mm, respectively. The population random errors in AP, ML and SI directions were 2·09, 1·85 and 2·29 mm, respectively. The SM of CTV to PTV calculated in accordance with the formula of ICRU 62 in AP, ML and SI directions were 2·51, 2·68 and 3·00 mm, respectively. And according to Stroom and Heijmen, formula were 4·23, 5·19 and 5·48 mm, respectively. And Van Herk et al. formula were 4·96, 6·17 and 6·45 mm, respectively. Findings: The SM of CTV to PTV in all directions, based on the formulas of ICRU 62, Stroom and Heijmen and van Herk et al., were equal to 2·73, 4·98 and 5·86 mm, respectively; these values were obtained by averaging the margins in all directions.

Sign in / Sign up

Export Citation Format

Share Document